Zentalis Pharmaceuticals, Inc. Common Stock
Here’s whether Zentalis Pharmaceuticals, Inc. Common Stock (ZNTL) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+2.06% over 10 days); strong 1-year return of +140.5%. Concerns: below the 50-day MA (medium-term momentum negative); 3-month momentum negative (-12.1%). Currently 48.8% off its 52-week high. Score: +2/7.
ZNTL is holding above its long-term 200-day MA ($3.07) but has slipped below the 50-day MA ($4.32), pointing to short-term weakness in an otherwise intact trend. An RSI of 33.2 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +140.5% compares to +20.4% for SPY (beat the market by 120.2%). The current 48.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.